Skip to main content

Sequenom Signs On University of Tuebingen Institute as MassArray User

NEW YORK, Aug. 17 (GenomeWeb News) – Sequenom has signed on the University of Tuebingen in Germany as a user of its MassArray gene expression platform, the company said today.

Under the agreement, the Institute of Medical Genetics and the Microarray facility at the university will use the MassArray Quantitative Gene Expression application to validate existing microarray data and for additional research in Parkinson’s disease, Huntington’s disease and cancers.

The institute will also be a reference site for the system, Sequenom said.

The parties did not disclose the financial terms of the agreement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.